In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Pharma, Inc.

http://www.astellas.com

Latest From Astellas Pharma, Inc.

Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success

South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.

Deal Watch Asia Pacific

Designing A Better Future For Immuno-Oncology: The Power Of ‘Iterative Innovation’

We are at a pivotal point in the reassessment of our approach to innovation, with the value of ‘design thinking’ and an ‘iterative innovation approach’ becoming the most promising solutions to solving the scientific and biological challenges of the future.

C-Suite Speaks ImmunoOncology

Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.

Clinical Trials Gene Therapy

Price Negotiation In Part D: Big Savings On Revlimid, Ibrance, Xtandi Projected in CAP Analysis

As Democrats in the US Congress work to move legislation empowering the Health and Human Services Department to negotiate drug prices directly with manufacturers, the Center For American Progress releases an analysis on which drugs would be targeted by House bill HR 3 and how much prices could be reduced.

Pricing Debate Legislation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced Cell Technology, Inc.
    • Agensys, Inc.
    • Audentes Therapeutics, Inc.
    • Fujisawa GmbH
    • Ganymed Pharmaceuticals AG GmbH
    • iota Biosciences
    • Mytogen, Inc.
    • Nanna Therapeutics Limited
    • Perseid Therapeutics LLC
    • Potenza Therapeutics Inc.
    • Ocata Therapeutics, Inc.
    • OSI Pharmaceuticals, LLC (Cell Pathways
    • Prosidion)
    • Yamanouchi Pharmaceutical Co., Ltd.
    • Ogeda S.A.
    • Mitobridge, Inc.
    • Mitokyne, Inc.
    • Quethera Limited
    • Universal Cells, Inc.
    • Xyphos Biosciences, Inc.
UsernamePublicRestriction

Register